Dr Reddy’s is collaborating with innovator firms in China, Israel and the US largely in areas of unmet need, propelling its “Horizon-2” strategy that encompasses segments like biologics and cell and gene therapy, digital services and immuno-oncology NCEs, among others.

Dr Reddy’s is collaborating with innovator firms in China, Israel and the US largely in areas of unmet need, propelling its “Horizon-2” strategy that encompasses segments like biologics and cell and gene therapy, digital services and immuno-oncology NCEs, among others.

Fresenius Kabi has switched from a geographic to segment-focused quarterly disclosure, in an attempt to improve transparency across its four key business units, three of which have been identified as key growth drivers.

Rather than conduct most analytical characterization and non-clinical studies first, the hallmark of the US FDA approach, biosimilar sponsors are often initiating clinical trials about the same time.